This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Perrigo Company PLC
Drug Names(s): Ellavie, Estradiol metered-dose transdermal spray (MTDS), Estramist
Description: Evamist is a patented new-generation of transdermal spray delivery system in a small, hand-held spray designed to provide a preset dose of estradiol via the skin. Evamist is placed gently against the skin and an actuator button is pushed which releases a light spray containing a proprietary formulation of estradiol. Estradiol is released into the bloodstream on a sustained basis over 24 hours.
Acrux and Vivus
In February 2004, Vivus entered into exclusive licensing agreements with Acrux under which it agreed to develop and, if approved, commercialize Luramist and Evamist in the United States for various female health applications. Vivus agreed to grant Acrux's subsidiary a non-exclusive, royalty-free license outside the United States for any MDTS products containing improvements Vivus has made to the licensed intellectual property and the option to obtain a non-exclusive, worldwide license for Vivus' intellectual property related to MDTS products. Vivus paid $3 million in upfront licensing fees to Acrux and agreed to make additional payments upon the completion of certain development, regulatory and sales milestones. Under the terms of the agreements, Vivus agreed to pay to Acrux combined licensing fees up to $4.3 million for the achievement of certain clinical development milestones, up to $6 million for achieving product approval milestones, and royalties on...See full deal structure in Biomedtracker
Partners: Vivus, Inc. Acrux Gedeon Richter Plc Aspen Pharmacare Holdings Limited
Pink Sheet Vivus/KV EvaMist approval
Additional information available to subscribers only: